biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
biote Corp.NASDAQ: BTMD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $980K rose 14.4% year over year, ahead of the +3.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.0% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.
Context
- Depreciation & amortization amounted to 1.9% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +14.4% holds above the trailing-twelve-month pace of +3.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.67M USD
- Year-over-year change
- +2.7%
- 4-year CAGR
- +27.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.67M | +2.7% |
| FY2024 | 2024-12-31 | 3.57M | +19.4% |
| FY2023 | 2023-12-31 | 2.99M | +36.2% |
| FY2022 | 2022-12-31 | 2.2M | +57.1% |
| FY2021 | 2021-12-31 | 1.4M | — |
Depreciation & Amortization vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 depreciation & amortization of $3.79M is the 5th largest of the 11 companies compared; the peer median is $2.54M.
- Its year-over-year change of +3.0% is the 4th highest of 10, against a peer median of -23.0%.
- Depreciation & amortization amounts to 2.0% of revenue for BTMD, versus a peer median of 12.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $429.44M | +48315.3% | -23.3% | 8364.7% | |
| LTM Mar 2026 | $6.49M | +61.5% | +5.3% | 19.2% | |
| LTM Mar 2026 | $5.54M | -27.5% | -26.6% | 4.8% | |
| LTM Mar 2026 | $3.84M | -23.0% | -14.6% | 334.6% | |
| LTM Mar 2026 | $3.79M | +3.0% | +18.6% | 2.0% | |
| LTM Mar 2026 | $2.99M | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $2.09M | -38.1% | +4.6% | — | |
| LTM Mar 2026 | $1.71M | -54.0% | -36.4% | 3.0% | |
| LTM Mar 2026 | $880K | +391.6% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding BTMD) | $2.54M | -23.0% | -18.4% | 12.0% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 32.62M | 1.32M | 3.32M | 46K | 27.05M |
| Depreciation & Amortization | 1.4M | 2.2M | 2.99M | 3.57M | 3.67M |
| Deferred Income Tax | 0 | (743K) | 721K | (2.9M) | 3.98M |
| Stock-Based Compensation | 0 | 82.18M | 9.06M | 8.74M | 8.92M |
| Change in Working Capital | (1.46M) | (35.81M) | (8.93M) | 9.93M | (8.25M) |
| Accounts Receivables | (752K) | (1.56M) | (505K) | (2.27M) | (958K) |
| Inventory | (5.76M) | (1.71M) | (6.1M) | 3.71M | (6.24M) |
| Accounts Payables | 1.61M | 416K | (165K) | 1.55M | 1.01M |
| Other Working Capital | 3.45M | (32.96M) | (2.16M) | 6.94M | (2.06M) |
| Other Non-Cash Items | 1.16M | (58.3M) | 19.72M | 25.85M | (165K) |
| Operating Cash Flow | 33.72M | (9.16M) | 26.88M | 45.24M | 35.19M |
| Capital Expenditures | (3.81M) | (1.84M) | (2.71M) | (6.43M) | (5.02M) |
| Acquisitions (Net) | 0 | 0 | 0 | (11.84M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2.36M) | (1.51M) | (2.35M) | (526K) | (1.85M) |
| Investing Cash Flow | (3.81M) | (1.84M) | (2.71M) | (18.8M) | (6.86M) |
| Debt Repayment | (5M) | 84.38M | (6.25M) | (6.25M) | (1.25M) |
| Common Stock Issued | 0 | 442K | 144K | 282K | 368K |
| Common Stock Repurchased | 0 | (424K) | 0 | (5.6M) | (3.37M) |
| Dividends Paid | (11.4M) | (12.89M) | (8.69M) | (4.74M) | (1.73M) |
| Other Financing Activities | (3.94M) | (8.05M) | 420K | (59.77M) | (37.58M) |
| Financing Cash Flow | (20.34M) | 63.46M | (14.38M) | (76.08M) | (43.56M) |
| Effect of Forex Changes | (12K) | 0 | (19K) | (22K) | 6K |
| Net Change in Cash | 9.56M | 52.47M | 9.77M | (49.66M) | (15.22M) |
| Free Cash Flow | 29.91M | (11M) | 24.17M | 38.81M | 30.18M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.